Standardized Corosolic Acid (1%) Study

Study In 1998, a crossover, placebo-controlled clinical study was conducted at the Tokyo Jikeikai Medical School in Japan with 24 subjects. The criteria for including subjects in this study were mild case of insulin independent diabetes, inability to tolerate glucose burden, glucose levels of 110mg/deciliter (fasting level) and subjects older than 20 years of age.

The subjects were given orally either a placebo or 3 tablets of 250mg each, after each meal three times daily. The daily total dose of Corosolic acid was 0.16 mg, the active ingredient of Glucosol™. The results of this study clearly demonstrate that Glucosol is effective in reducing blood glucose levels even in short-term (4 weeks) treatment, with no signs of adverse effects.

Furthermore, even a one-time dose leaves a memory-effect for blood glucose control. Compared to the placebo group, a statistically significant drop in the average blood glucose level is observed with the administration of Glucosol Blood glucose level dropped from 153.9 mg/deciliter, before the Glucosol dose, to 133.1 mg/deciliter, after the dose.

Back to Clinical Trials Main Page